|Slideshows|May 28, 2021

6 Lessons From a Tragedy

There are beautiful things that you can only see in the dark.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

BySarah Cheema, MD,Andrew Canto, MD,Nicolas Badre, MD

July 21st 2026

Postpartum Depression: Zuranolone, Emerging Therapies, and Screening for Birth Trauma

ByKatie Unverferth, MD

July 11th 2026

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

ByCharles Debattista, MD

July 10th 2026

Potential of GABAergic Medications in MDD

ByGustavo Alva, MD, DFAPA,Jason Kellogg, MD

July 2nd 2026

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

ByJoseph F. Goldberg, MD,Roy Perlis, MD

June 30th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

6 Lessons From a Tragedy

Related Content

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

Postpartum Depression: Zuranolone, Emerging Therapies, and Screening for Birth Trauma

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

Potential of GABAergic Medications in MDD

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

Remlifanserin for the Treatment of Alzheimer Disease Psychosis Receives FDA Fast Track Designation

Future DSM Plans Overlook Core Problem of Validity

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

Assessing Antipsychotics as Antidepressant Adjuncts